Literature DB >> 26651946

Molecular Basis for Antibody-Mediated Neutralization of New World Hemorrhagic Fever Mammarenaviruses.

Selma Mahmutovic1, Lars Clark1, Silvana C Levis2, Ana M Briggiler2, Delia A Enria2, Stephen C Harrison3, Jonathan Abraham4.   

Abstract

In the Western hemisphere, at least five mammarenaviruses cause human viral hemorrhagic fevers with high case fatality rates. Junín virus (JUNV) is the only hemorrhagic fever virus for which transfusion of survivor immune plasma that contains neutralizing antibodies ("passive immunity") is an established treatment. Here, we report the structure of the JUNV surface glycoprotein receptor-binding subunit (GP1) bound to a neutralizing monoclonal antibody. The antibody engages the GP1 site that binds transferrin receptor 1 (TfR1)-the host cell surface receptor for all New World hemorrhagic fever mammarenaviruses-and mimics an important receptor contact. We show that survivor immune plasma contains antibodies that bind the same epitope. We propose that viral receptor-binding site accessibility explains the success of passive immunity against JUNV and that this functionally conserved epitope is a potential target for therapeutics and vaccines to limit infection by all New World hemorrhagic fever mammarenaviruses.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26651946      PMCID: PMC4685251          DOI: 10.1016/j.chom.2015.11.005

Source DB:  PubMed          Journal:  Cell Host Microbe        ISSN: 1931-3128            Impact factor:   21.023


  36 in total

Review 1.  Arenaviruses other than Lassa virus.

Authors:  Rémi N Charrel; Xavier de Lamballerie
Journal:  Antiviral Res       Date:  2003-01       Impact factor: 5.970

2.  Mechanism of human antibody-mediated neutralization of Marburg virus.

Authors:  Andrew I Flyak; Philipp A Ilinykh; Charles D Murin; Tania Garron; Xiaoli Shen; Marnie L Fusco; Takao Hashiguchi; Zachary A Bornholdt; James C Slaughter; Gopal Sapparapu; Curtis Klages; Thomas G Ksiazek; Andrew B Ward; Erica Ollmann Saphire; Alexander Bukreyev; James E Crowe
Journal:  Cell       Date:  2015-02-26       Impact factor: 41.582

3.  Past, present, and future of arenavirus taxonomy.

Authors:  Sheli R Radoshitzky; Yīmíng Bào; Michael J Buchmeier; Rémi N Charrel; Anna N Clawson; Christopher S Clegg; Joseph L DeRisi; Sébastien Emonet; Jean-Paul Gonzalez; Jens H Kuhn; Igor S Lukashevich; Clarence J Peters; Victor Romanowski; Maria S Salvato; Mark D Stenglein; Juan Carlos de la Torre
Journal:  Arch Virol       Date:  2015-07       Impact factor: 2.574

4.  Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection.

Authors:  Kartik Chandran; Nancy J Sullivan; Ute Felbor; Sean P Whelan; James M Cunningham
Journal:  Science       Date:  2005-04-14       Impact factor: 47.728

5.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

6.  Viral receptor-binding site antibodies with diverse germline origins.

Authors:  Aaron G Schmidt; Matthew D Therkelsen; Shaun Stewart; Thomas B Kepler; Hua-Xin Liao; M Anthony Moody; Barton F Haynes; Stephen C Harrison
Journal:  Cell       Date:  2015-05-07       Impact factor: 41.582

7.  Host-species transferrin receptor 1 orthologs are cellular receptors for nonpathogenic new world clade B arenaviruses.

Authors:  Jonathan Abraham; Jo Ann Kwong; César G Albariño; Jiajie G Lu; Sheli R Radoshitzky; Jorge Salazar-Bravo; Michael Farzan; Christina F Spiropoulou; Hyeryun Choe
Journal:  PLoS Pathog       Date:  2009-04-03       Impact factor: 6.823

8.  Dual host-virus arms races shape an essential housekeeping protein.

Authors:  Ann Demogines; Jonathan Abraham; Hyeryun Choe; Michael Farzan; Sara L Sawyer
Journal:  PLoS Biol       Date:  2013-05-28       Impact factor: 8.029

Review 9.  Envelope glycoprotein of arenaviruses.

Authors:  Dominique J Burri; Joel Ramos da Palma; Stefan Kunz; Antonella Pasquato
Journal:  Viruses       Date:  2012-10-17       Impact factor: 5.048

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  27 in total

1.  Myristoylation of the Arenavirus Envelope Glycoprotein Stable Signal Peptide Is Critical for Membrane Fusion but Dispensable for Virion Morphogenesis.

Authors:  Joanne York; Jack H Nunberg
Journal:  J Virol       Date:  2016-08-26       Impact factor: 5.103

2.  A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins.

Authors:  Xavier Carnec; Mathieu Mateo; Audrey Page; Stéphanie Reynard; Jimmy Hortion; Caroline Picard; Elsie Yekwa; Laura Barrot; Stéphane Barron; Audrey Vallve; Hervé Raoul; Caroline Carbonnelle; François Ferron; Sylvain Baize
Journal:  J Virol       Date:  2018-05-29       Impact factor: 5.103

3.  Differences in Glycoprotein Complex Receptor Binding Site Accessibility Prompt Poor Cross-Reactivity of Neutralizing Antibodies between Closely Related Arenaviruses.

Authors:  Rachel B Brouillette; Elisabeth K Phillips; Natarajan Ayithan; Wendy Maury
Journal:  J Virol       Date:  2017-03-13       Impact factor: 5.103

4.  Monoclonal Antibodies with Neutralizing Activity and Fc-Effector Functions against the Machupo Virus Glycoprotein.

Authors:  Fatima Amanat; James Duehr; Cheng Huang; Slobodan Paessler; Gene S Tan; Florian Krammer
Journal:  J Virol       Date:  2020-02-14       Impact factor: 5.103

5.  Differential Antibody-Based Immune Response against Isolated GP1 Receptor-Binding Domains from Lassa and Junín Viruses.

Authors:  Aliza Borenstein-Katz; Anastasiya Shulman; Hedva Hamawi; Orith Leitner; Ron Diskin
Journal:  J Virol       Date:  2019-04-03       Impact factor: 5.103

Review 6.  Native functionality and therapeutic targeting of arenaviral glycoproteins.

Authors:  Max Crispin; Antra Zeltina; Nicole Zitzmann; Thomas A Bowden
Journal:  Curr Opin Virol       Date:  2016-04-19       Impact factor: 7.090

7.  Adenoviral vector-based vaccine is fully protective against lethal Lassa fever challenge in Hartley guinea pigs.

Authors:  Junki Maruyama; Elizabeth J Mateer; John T Manning; Rachel Sattler; Alexey V Seregin; Natalya Bukreyeva; Frank R Jones; Joseph P Balint; Elizabeth S Gabitzsch; Cheng Huang; Slobodan Paessler
Journal:  Vaccine       Date:  2019-09-24       Impact factor: 3.641

8.  Bivalent Junin & Machupo experimental vaccine based on alphavirus RNA replicon vector.

Authors:  Dylan M Johnson; Jenny D Jokinen; Min Wang; Tia Pfeffer; Irina Tretyakova; Ricardo Carrion; Anthony Griffiths; Peter Pushko; Igor S Lukashevich
Journal:  Vaccine       Date:  2020-02-25       Impact factor: 3.641

9.  Structural basis for antibody-mediated neutralization of Lassa virus.

Authors:  Kathryn M Hastie; Michelle A Zandonatti; Lara M Kleinfelter; Megan L Heinrich; Megan M Rowland; Kartik Chandran; Luis M Branco; James E Robinson; Robert F Garry; Erica Ollmann Saphire
Journal:  Science       Date:  2017-06-02       Impact factor: 47.728

10.  Convergent immunological solutions to Argentine hemorrhagic fever virus neutralization.

Authors:  Antra Zeltina; Stefanie A Krumm; Mehmet Sahin; Weston B Struwe; Karl Harlos; Jack H Nunberg; Max Crispin; Daniel D Pinschewer; Katie J Doores; Thomas A Bowden
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-19       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.